Pharmaceutical companies that were trying to overcome the patent of Daewon's anti-inflammatory pain reliever Pelubi (Pelubiprofen) gave up.
After Mother's and Hutecs voluntarily withdrew the request for a referee last year, Nexpharm was recently added, leaving only three of the six challengers. Some of the companies that voluntarily withdrew are said to have failed to develop the formulation.

According to the pharmaceutical industry on the 10th, Nexpharm withdrew the trial to confirm the passive scope of rights for the Pelubi recently filed against Daewon. The third step after Mother's and Hutecs. Hutecs gave up its patent challenge in September of last year and in October of the same year.